Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer

Diagnostic Pathology

Volumn 4, Issue 1, 2009, Pages

  Casorzo, Laura ^a   Corigliano, Mara ^a   Ferrero, Paolo ^a   Venesio, Tiziana ^a   Risio, Mauro ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73249140354     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-4-36     Document Type: Article

References (42)

1. Gefitinib (ZD Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. F Barlési C Tchouhadjian C Doddoli P Villani L Greillier JP Kleisbauer P Thomas P Astoul, Fundam Clin Pharmacol 1839 19 385 93 10.1111/j.1472-8206.2005.00323.x
2. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. G Giaccone, J Clin Oncol 2005 23 3235 42 10.1200/JCO.2005.08.409 15886311
3. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. G Giaccone, Ann Oncol 2005 16 538 48 10.1093/annonc/mdi129 15746148
4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska DN Louis DC Christiani J Settleman DA Haber, N Engl J Med 2004 350 2129 39 10.1056/NEJMoa040938 15118073
5. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. JG Paez PA Jänne JC Lee S Tracy H Greulich S Gabriel P Herman FJ Kaye N Lindeman TJ Boggon K Naoki H Sasaki Y Fujii MJ Eck WR Sellers BE Johnson M Meyerson, Science 2004 304 1497 500 10.1126/science.1099314 15118125
6. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. W Pao V Miller M Zakowski J Doherty K Politi I Sarkaria B Singh R Heelan V Rusch L Fulton E Mardis D Kupfer R Wilson M Kris H Varmus, Proc Natl Acad Sci USA 2004 101 13306 11 15329413 10.1073/pnas.0405220101 (Pubitemid 39209661)
7. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. W Pao VA Miller, J Clin Oncol 2005 23 2556 68 10.1200/JCO.2005.07. 799 15767641
8. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. GJ Riely KA Politi VA Miller W Pao, Clin Cancer Res 2006 12 7232 41 10.1158/1078-0432.CCR-06-0658 17189394
9. Epidermal growth factor receptor mutations in lung cancer. SV Sharma DW Bell J Settleman DA Haber, Nat Rev Cancer 2007 7 169 81 10.1038/nrc2088 17318210
10. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. DA Eberhard BE Johnson LC Amler AD Goddard SL Heldens RS Herbst WL Ince PA Jänne T Januario DH Johnson P Klein VA Miller MA Ostland DA Ramies D Sebisanovic JA Stinson YR Zhang S Seshagiri KJ Hillan, J Clin Oncol 2005 23 5900 9 10.1200/JCO.2005.02.857 16043828
11. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. DW Bell TJ Lynch SM Haserlat PL Harris RA Okimoto BW Brannigan DC Sgroi B Muir MJ Riemenschneider RB Iacona AD Krebs DH Johnson G Giaccone RS Herbst C Manegold M Fukuoka MG Kris J Baselga JS Ochs DA Haber, J Clin Oncol 2005 23 8081 92 10.1200/JCO.2005.02.7078 16204011
12. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli L Bemis J Haney S Witta K Danenberg I Domenichini V Ludovini E Magrini V Gregorc C Doglioni A Sidoni M Tonato WA Franklin L Crino PA Bunn Jr M Varella-Garcia, J Natl Cancer Inst 2005 97 643 55 15870435
13. Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. FR Hirsch M Varella-Garcia J McCoy H West AC Xavier P Gumerlock PA Bunn Jr WA Franklin J Crowley DR Gandara, J Clin Oncol 2005 23 6838 45 10.1200/JCO.2005.01.2823 15998906
14. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. DW Bell TJ Lynch SM Haserlat PL Harris RA Okimoto BW Brannigan DC Sgroi B Muir MJ Riemenschneider RB Iacona AD Krebs DH Johnson G Giaccone RS Herbst C Manegold M Fukuoka MG Kris J Baselga JS Ochs DA Haber, J Clin Oncol 2005 23 8081 92 10.1200/JCO.2005.02.7078 16204011
15. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. F Cappuzzo C Ligorio PA Jänne L Toschi E Rossi R Trisolini D Paioli AJ Holmes E Magrini G Finocchiaro S Bartolini A Cancellieri F Ciardiello M Patelli L Crino M Varella-Garcia, J Clin Oncol 2007 25 2248 55 10.1200/JCO.2006.09.4300 17538169
16. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). F Cappuzzo C Ligorio L Toschi E Rossi R Trisolini D Paioli E Magrini G Finocchiaro S Bartolini A Cancellieri FR Hirsch L Crino M Varella-Garcia, J Thorac Oncol 2007 2 423 9 10.1097/01.JTO.0000268676.79872.9b 17473658
17. National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. CQ Zhu G da Cunha Santos K Ding A Sakurada JC Cutz N Liu T Zhang P Marrano M Whitehead JA Squire S Kamel-Reid L Seymour FA Shepherd MS Tsao, J Clin Oncol 2008 26 4268 75 10.1200/JCO.2007.14.8924 18626007
18. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. T Takano Y Ohe H Sakamoto K Tsuta Y Matsuno U Tateishi S Yamamoto H Nokihara N Yamamoto I Sekine H Kunitoh T Shibata T Sakiyama T Yoshida T Tamura, J Clin Oncol 2005 23 6829 37 10.1200/JCO.2005.01.0793 15998907
19. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. FR Hirsch M Varella-Garcia F Cappuzzo J McCoy L Bemis AC Xavier R Dziadziuszko P Gumerlock K Chansky H West AF Gazdar L Crino DR Gandara WA Franklin PA Bunn Jr, Ann Oncol 2007 18 752 60 10.1093/annonc/mdm003 17317677
20. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. DA Eberhard G Giaccone BE Johnson, J Clin Oncol 2008 26 983 94 10.1200/JCO.2007.12.9858 18281673
21. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridisation assay. M Varella-Garcia, Diagn Pathol 2006 1 19 16911776 10.1186/1746-1596-1-19
22. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. FR Hirsch S Witta, Curr Opin Oncol 2005 17 118 22 10.1097/01.cco.0000155059.39733.9d 15725915
23. Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. G Metro G Finocchiaro F Cappuzzo, Ann Oncol 2006 17 Suppl 2 i42 45 10.1093/annonc/mdj920 16608980
24. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. L Toschi F Cappuzzo, Oncologist 2007 12 211 20 10.1634/theoncologist.12-2-211 17296817
25. "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?". CL Hann JR Brahmer, Curr Treat Options Oncol 2007 8 28 37 10.1007/s11864-007-0024-2 17634830
26. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. M Ladanyi W Pao, Mod Pathol 2008 21 Suppl 2 16 22 10.1038/modpathol.3801018 18437168
27. EGFR assays in lung cancer. S Dacic, Adv Anat Pathol 2008 15 241 7 10.1097/PAP.0b013e31817bf5a9 18580100
28. Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations? BE Johnson PA Jänne, Clin Oncol 2005 23 6813 6 10.1200/JCO.2005.97.008 (Pubitemid 46260266)
29. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. H Sasaki K Endo K Okuda O Kawano N Kitahara H Tanaka A Matsumura K Iuchi M Takada M Kawahara T Kawaguchi H Yukiue T Yokoyama M Yano Y Fujii, J Cancer Res Clin Oncol 2008 134 569 77 10.1007/s00432-007-0320-z 17932690
30. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. TJ Pugh G Bebb L Barclay M Sutcliffe J Fee C Salski R O'Connor C Ho N Murray B Melosky J English J Vielkind D Horsman JJ Laskin MA Marra, BMC Cancer 2007 7 128 17626639 10.1186/1471-2407-7-128 (Pubitemid 47337236)
31. Chromosome abnormalities in human non-small cell lung cancer. JR Testa JM Siegfried, Cancer Res 1992 52 Suppl 9 2702s 2706s
32. Chromosomal imbalances in human lung cancer. BR Balsara JR Testa, Oncogene 2002 21 6877 83 10.1038/sj.onc.1205836 12362270
33. Clinical relevance of chromosome abnormalities in non-small cell lung cancer. M Feder JM Siegfried A Balshem S Litwin SM Keller Z Liu JR Testa, Cancer Genet Cytogenet 1998 102 25 31 10.1016/S0165-4608(97)00274-4 9530336
34. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. I Vanden Bempt V Vanhentenrijk M Drijkoningen I Wlodarska P Vandenberghe C De Wolf-Peeters, Histopathology 2005 46 431 41 10.1111/j.1365-2559.2005.02112.x 15810955
35. Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing. I Vanden Bempt P Van Loo M Drijkoningen P Neven A Smeets MR Christiaens R Paridaens C De Wolf-Peeters, J Clin Oncol 2008 26 4869 74 10.1200/JCO.2007.13.4296 18794552
36. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. T Okabe I Okamoto K Tamura M Terashima T Yoshida T Satoh M Takada M Fukuoka K Nakagawa, Cancer Res 2007 67 2046 53 10.1158/0008-5472.CAN-06-3339 17332333
37. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. M Nomura H Shigematsu L Li M Suzuki T Takahashi P Estess M Siegelman Z Feng H Kato A Marchetti JW Shay MR Spitz II Wistuba JD Minna AF Gazdar, PLoS Med 2007 4 125 17455987 10.1371/journal.pmed.0040125 (Pubitemid 46658773)
38. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. AJ Wong SH Bigner DD Bigner KW Kinzler SR Hamilton B Vogelstein, Proc Natl Acad Sci USA 1987 84 6899 903 3477813 10.1073/pnas.84.19.6899
39. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. TA Libermann HR Nusbaum N Razon R Kris I Lax H Soreq N Whittle MD Waterfield A Ullrich J Schlessinger, Nature 1985 313 144 7 10.1038/313144a0 2981413
40. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Y Yatabe T Takahashi T Mitsudomi, Cancer Res 2008 68 2106 11 10.1158/0008-5472.CAN-07-5211 18381415
41. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Soh S Toyooka S Ichihara H Asano N Kobayashi H Suehisa H Otani H Yamamoto K Ichimura K Kiura AF Gazdar H Date, J Thorac Oncol 2008 3 340 7 18379350 10.1097/JTO.0b013e318168d20a
42. Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. R Morinaga I Okamoto Y Fujita T Arao M Sekijima K Nishio H Ito M Fukuoka J Kadota K Nakagawa, Cancer Sci 2008 99 2455 60 10.1111/j.1349-7006.2008.00962.x 18957054